Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
BUD · NYSE
- $83.97
- $160.02B
- Open
- —
- —
- $81.02 - $82.06
- $59.90 - $86.60
- —
- —
- 3.43M
About Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev brews and sells beer under a portfolio of approximately 500 brands, including Budweiser, Corona Extra, Michelob Ultra and Stella Artois, alongside regional labels such as Brahma, Jupiler and Quilmes. Its portfolio also includes non-beer beverages. It earns revenue by selling these drinks, although the supplied evidence does not provide segment contributions or financial results. Its products serve consumers through commercial buyers and distribution channels. The brand roster indicates a broad international business, but the evidence does not quantify current production, revenue, market share or employee scale.
Notable Price Movement
- Oct 19-23$84.262.02%
BUD rose 6.80%, from $77.33 to $82.59, over the supplied trading interval. It advanced at every listed close, gaining from $77.33 on October 9 to $81.28 on October 15 before adding to $82.59 on October 16; there was no material reversal. MarketBeat reported that the shares had broken above their 200-day moving average, a technical signal that coincided with the sustained climb. Bernstein maintained its Buy rating on October 15, while TD Cowen cut its target from $89 to $85 on October 13; neither action halted the advance. Barron’s framed BUD as a buy despite drinkers abandoning beer, and Zacks described it as a long-term momentum stock. The supplied evidence does not establish a broader market driver or a single catalyst for the move.
- Aug 3-7$83.763.15%
BUD gained $1.39, or 1.67%, over the week, rising from $83.20 to $84.59. The stock climbed from $83.20 on July 28 to $86.48 by July 31 as second-quarter reports highlighted higher revenue, earnings and free cash flow, returning beer-volume growth and global market-share gains. The advance was tempered by Zacks’ report that AB InBev missed quarterly earnings and revenue estimates, although it reaffirmed its 2026 view. BUD then gave back most of the prior week’s advance on August 3, falling to $84.05, before recovering modestly on August 4. No other company-specific catalyst was supplied; the week’s movement was dominated by the earnings assessment and its mixed implications.
